Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Hold” by Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has been assigned a consensus rating of “Hold” from the nine analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $3.20.

Several brokerages have issued reports on GOSS. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target on the stock in a report on Tuesday. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Finally, HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Monday, July 27th.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Gossamer Bio by 32.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 1,098,914 shares of the company’s stock worth $181,000 after acquiring an additional 270,195 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Gossamer Bio by 66.5% during the first quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock valued at $1,041,000 after acquiring an additional 1,267,056 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Gossamer Bio by 233.4% during the first quarter. ADAR1 Capital Management LLC now owns 287,531 shares of the company’s stock valued at $94,000 after acquiring an additional 503,100 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio during the first quarter valued at $3,363,000. Finally, Renaissance Technologies LLC increased its position in Gossamer Bio by 84.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,217,868 shares of the company’s stock worth $400,000 after purchasing an additional 558,980 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Down 4.9%

Gossamer Bio stock opened at $0.17 on Friday. Gossamer Bio has a 52 week low of $0.11 and a 52 week high of $3.87. The firm’s 50-day simple moving average is $0.17 and its 200 day simple moving average is $0.74. The firm has a market capitalization of $39.78 million, a PE ratio of -0.21 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $4.67 million. On average, research analysts expect that Gossamer Bio will post -0.39 EPS for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.